Email a Friend
To: (email address)
From: (email address)
Email Subject:
Note: (optional)
255 character limit
Since 2003, as an adjunct to diet, CRESTOR® (rosuvastatin calcium), a statin medication, has been indicated to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.1,2
In November 2007, CRESTOR was approved to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels.1,2
In February 2010, CRESTOR was also approved to reduce the risk of myocardial infarction, stroke, and arterial revascularization procedures in patients without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men ≥50 and women ≥60), high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease.1,2
With proven efficacy in reducing LDL-C, increasing HDL-C, slowing the progression of atherosclerosis, and a primary prevention of CVD indication, CRESTOR can help you in treating your appropriate patients.1
Select one of the boxes below to learn more about CRESTOR.
You may report side effects related to AstraZeneca products by clicking here.